Celldex Therapeutics - Precision Targeted Immunotherapies
Celldex in the News
-
June 11, 2008 AVANT Announces Vaccine Adjuvant Licenses with 3M
Apr 22, 2008 ABC News segment on CDX-110
Apr 16, 2008 PFIZER and AVANT Enter Into Licensing and Development Agreement for Novel Therapeutic Vaccine Candidate for Brain Cancer
Jan 14, 2008 LA Times Feature on CDX-110
Nov 8, 2007 "An Injection of Hope"
May 2, 2007 ABC News coverage on Celldex Vaccine
April 30, 2007 Business Week story on CDX-110
March, 2007 Celldex Vaccine Program featured on CBS Evening News
Watch the Related CBS Videos Brain Surgeon Beats Cancer Odds A Doctor's Own Cancer Battle Doctor Heal Thyself
Contact & Directions
Celldex Fact Sheet
 |
Download the Celldex Fact Sheet (.pdf) |
About Celldex
Celldex is an innovative biotechnology company focused on the discovery, development and commercialization of targeted immunotherapies. Our core focus includes the use of tumor-specific targets and human monoclonal antibodies as precision delivered therapeutic agents for the treatment of cancer, infectious diseases and immune system disorders through our novel ‘active immunization’ approach.
Featured Links
- Current Clinical Trial in Cancer - A Phase II/III Randomized Study of CDX-110 with Radiation and Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme
- ASCO 2007 Poster - Temozolomide as a Vaccine Adjuvant in GBM
- ACSO 2007 Poster – APC-targeted hCGb Vaccine for Cancer Therapy
- Celldex Therapeutics Initiates a Definitive Phase 2/3 Clinical Trial of CDX-110 in Patients with Glioblastoma Multiforme
- Learn more about APC Technology - Celldex's proprietary technology platform uses fully human monoclonal antibodies administered directly to patients to target and stimulate dendritic cells and macrophages.